Report LibraryAll Reports
Prostate Cancer KOL Interview – US
November 10, 2020
A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for
prostate cancer. Diagnostic testing and unmet needs are also discussed. Key pipeline assets highlighted include Keytruda, Tecentriq, ipatasertib,
DCVAC/PCa, capivasertib, Lutetium 177Lu-PSMA-617, and Cabometyx.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only) .
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200- 2357.
For our disclosures, please read the Biomedtracker Research Standards.
|Indications Covered:||Prostate Cancer|